Search clinical trials for: TAK-901

Total 7947 results

1
2
3
4
5
6
7
8
9
10
...
158
159
›

Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma

Lymphoma | Advanced Solid Tumors

United States
Takeda

Completed

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Japanese Healthy Adult Male Participants

Japan
Takeda

Terminated

A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)

Nausea and Vomitting

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteer

United States
Takeda

Terminated

A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System

Neoplasms | Lymphoma | Hematologic Neoplasms

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

Nonhematologic Neoplasms, Advanced

Japan
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Advanced Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
Takeda

Withdrawn

Bioavailability and Food Effect Study of Two Formulations of TAK-906

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Colorectal Cancer | Esophageal Neoplasms | Metastatic Pancreatic Cancer | Carcinoma, Non-small-cell Lung

United States, Japan
Presage Biosciences
Takeda

Completed

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Head and Neck Cancer

United States
Takeda

Terminated

A Study of TAK-951 in Healthy Adults

Healthy Volunteers

United States
Takeda
COUR Pharmaceutical Development Company, Inc.

Completed

Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

Celiac Disease

United States
Takeda

Terminated

An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

Solid Tumors

Hungary
Takeda

Recruiting

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Celiac Disease

United States, Australia, Canada, New Zealand
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Perioperative Period of Malignant Tumor Patients

Perioperative Period | Malignant Tumor of Bone
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy

Chemotherapy | Malignant Tumor
Millennium Pharmaceuticals, Inc.

Completed

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Healthy Volunteers

United States
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

Colorectal Cancer

Taiwan
Takeda
COUR Pharmaceuticals Development Company, Inc.

Completed

Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

Celiac Disease

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors

Neoplasms, Advanced Solid

Netherlands
Takeda

Recruiting

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Colorectal Cancer | Non-small Cell Lung Cancer (NSCLC) | Squamous Cell Cancer of Head and Neck (SCCHN)

United States, Australia, Korea, Republic of, United Kingdom
University of Tasmania

Enrolling by invitation

TapTalkTest Project:Development of a Non-invasive Screening Test to Detect Risk of Alzheimer's Disease Pathology (TapTalkTest)

Dementia | Alzheimer Disease | Speech Disorders | Movement Abnormalities

Australia
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Oregon Research Institute

Recruiting

A Study of Dual-task Exercise Training to Prevent Falls Among Older Adults With Mild Cognitive Impairment

Aging | Mild Cognitive Impairment | Accidental Falls

United States
Takeda

Recruiting

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Alpha1-Antitrypsin Deficiency

Belgium, Italy, Germany, Canada, United States, Poland, France, Switzerland, Portugal, Austria, Sweden, Spain
US Department of Veterans Affairs

Completed

Fitness and Daily Function in Adults

Cardiovascular Disease

United States
Afyonkarahisar Health Sciences University

Recruiting

Dual Task Gait Performance in Pediatric Oncology Patients

Pediatric Cancer

Turkey
St. Luke's-Roosevelt Hospital Center

Completed

Transplant and Addiction Project (TAP) - 1

Substance-Related Disorders | End Stage Liver Disease | End Stage Renal Disease

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Alpha1-Antitrypsin Deficiency

United States, Belgium, Czechia, Switzerland, Canada, Australia, Germany, United Kingdom, Spain, Austria, France, Netherlands, Portugal, Italy, Poland, Brazil, Sweden
Takeda

Terminated

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Relapsed and/or Refractory Multiple Myeloma (RRMM)

United States, Canada
University of Iceland
Uppsala University

Recruiting

The Lóa Study: a Brief Digital Intervention for Women with Intrusive Memories in the SAGA Cohort

Intrusive Memories of Traumatic Event(s)

Iceland
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
Takeda

Withdrawn

A Phase 1, Single and Multiple Dose Study of TAK-137

Healthy Japanese Adult Male

Japan
Neurocrine Biosciences
Takeda

Terminated

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Schizophrenia, Cerebellar Ataxia

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

Idiopathic Hypersomnia

United States, Japan
Takeda

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Friedreich Ataxia

United States
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet

Japanese Healthy Adult Male

Japan
Takeda

Completed

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

Dose Finding Study
Kaohsiung Medical University Chung-Ho Memorial...

Unknown

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Taiwan
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Postoperative Gastrointestinal Dysfunction

United States, Germany
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Depressive Disorder

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States

1
2
3
4
5
6
7
8
9
10
...
158
159
›

3

Subscribe